Oncimmune is a leading early cancer detection company

  • Our patented autoantibody assay technology can detect autoantibodies produced in response to cancer 4 years or more before diagnosis1,2
  • Oncimmune’s early cancer detection technology can be applied to many solid tumor cancer types
  • Our simple blood test for lung cancer, EarlyCDT®-Lung, is available now through physicians and is reimbursable in the US. In the UK and other regions, it is available self-pay. Over 155,000 commercial tests have been sold.
  • EarlyCDT-Lung can aid in the risk assessment of lung nodules and for early detection of lung cancer in high-risk patients .
  • Oncimmune launched a test for liver cancer in early 2018. We are developing tests for other solid tumour cancers.
  • Oncimmune Ltd is headquartered in Nottingham, UK. Testing is conducted in our CLIA-approved laboratory, based in De Soto, Kansas, USA. We also offer test kits for use in professional laboratories outside the US.

1 Zhong L, et al. Profiling tumour-associated antibodies for early detection of non-small cell lung cancer. J Thor Oncol 2006; 1:513-519.
2 Jett J, et al. Determination of the detection lead time for autoantibody biomarkers in early stage lung cancer using the UKCTOCS cohort. J Thor Oncol 2017; 12(11):S2170.



Electronic versions of the materials you are seeking to access are being made available on this website by Oncimmune Holdings plc (the “Company”).

These materials are not directed to nor are they intended for access by persons located or resident in the United States, Australia, Canada, South Africa, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

None of the securities of Company discussed or referred to in the materials you are seeking to access have been registered under the US Securities Act or 1933, as amended (the “Securities Act”) and may not be offered, sold, pledged or otherwise transferred except (1) in an offshore transaction meeting the requirements of Rule 903 or Rule 904 of Regulation S under the Securities Act, (2) pursuant to an effective registration statement under the Securities Act, or (3) pursuant to an available exemption from the registration requirements of the Securities Act, in each case in accordance with all applicable securities laws.

By clicking the “SUBMIT” button below you confirm that you (1) have read and understood the information set out above, (2) agree to be bound by its terms, (3) are not located in the United States and do not have a registered address in, and are not resident or located in, Australia, Canada, South Africa or Japan and (4) are permitted under applicable law and regulation to proceed to the following parts of this website.

Please click on the button below to confirm that you have read, understood and agree with the disclaimer above.

Yes, I accept No, I don't accept